These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25193989)

  • 1. High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.
    Reijm EA; Timmermans AM; Look MP; Meijer-van Gelder ME; Stobbe CK; van Deurzen CHM; Martens JWM; Sleijfer S; Foekens JA; Berns PMJJ; Jansen MPHM
    Ann Oncol; 2014 Nov; 25(11):2185-2190. PubMed ID: 25193989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
    Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
    Jansen MP; Reijm EA; Sieuwerts AM; Ruigrok-Ritstier K; Look MP; Rodríguez-González FG; Heine AA; Martens JW; Sleijfer S; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2012 Jun; 133(3):937-47. PubMed ID: 22094936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
    Alford SH; Toy K; Merajver SD; Kleer CG
    Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
    Jansen MP; Sieuwerts AM; Look MP; Ritstier K; Meijer-van Gelder ME; van Staveren IL; Klijn JG; Foekens JA; Berns EM
    J Clin Oncol; 2007 Feb; 25(6):662-8. PubMed ID: 17308270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
    Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
    Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EZH2 Expression and Survival for ER+/tamoxifen Treated Breast Cancer Patients with rs2302427 C>G: A Novel Prognostic and Risk Predictive Biomarker.
    Gautam N; Kaur S; Kashyap S
    Arch Med Res; 2023 Jul; 54(5):102852. PubMed ID: 37438214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
    Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
    Gong Y; Huo L; Liu P; Sneige N; Sun X; Ueno NT; Lucci A; Buchholz TA; Valero V; Cristofanilli M
    Cancer; 2011 Dec; 117(24):5476-84. PubMed ID: 21713757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth.
    Corbin J; Yu X; Jin J; Cai L; Wang GG
    Oncogene; 2024 Aug; 43(36):2722-2736. PubMed ID: 39112519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
    Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
    Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy.
    van der Willik KD; Timmermans MM; van Deurzen CH; Look MP; Reijm EA; van Zundert WJ; Foekens R; Trapman-Jansen AM; den Bakker MA; Westenend PJ; Martens JW; Berns EM; Jansen MP
    Am J Cancer Res; 2016; 6(2):270-84. PubMed ID: 27186402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
    Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
    Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.
    De Marchi T; Timmermans AM; Smid M; Look MP; Stingl C; Opdam M; Linn SC; Sweep FC; Span PN; Kliffen M; van Deurzen CH; Luider TM; Foekens JA; Martens JW; Umar A
    Oncotarget; 2016 Jan; 7(3):3098-110. PubMed ID: 26657294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.
    Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA
    J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.